NurExone Biologic (FRA:J90) Payments of Debt: €-0.02 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J90 NurExone Biologic Inc FRA:J90
40 GF Score
Price €0.29
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic Payments of Debt?

NurExone Biologic FRA:J90 -1.34% 40 Payments of Debt is €-0.02 Mil as of Mar. 2026. GuruFocus rates FRA:J90 with a GF Score™ of 40/100. The stock has 2 warning signs investors should review.

NurExone Biologic's Payments of Debt for the three months ended in Mar. 2026 was €-0.01 Mil.

NurExone Biologic's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.02 Mil.

NurExone Biologic Payments of Debt Related Terms

NurExone Biologic Payments of Debt Historical Data

* Premium members only.

The historical data trend for NurExone Biologic's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic Payments of Debt Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
0.00 -0.01 -0.03 -0.03 -0.02

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.01 -0.01 -0.01
FRA:J90
40GF Score
NurExone Biologic Inc FRA:J90
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NurExone Biologic Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-0.02 Mil mean?
NurExone Biologic (FRA:J90) has a Payments of Debt of €-0.02 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on NurExone Biologic and its competitors.
Is NurExone Biologic's Payments of Debt too high?
NurExone Biologic's current Payments of Debt is €-0.02 Mil. Overall, NurExone Biologic has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's Payments of Debt compare to VRTX and REGN?
NurExone Biologic's Payments of Debt of €-0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on NurExone Biologic and its competitors. NurExone Biologic's current Payments of Debt is €-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current Payments of Debt of €-0.02 Mil. The current Payments of Debt is €-0.02 Mil. NurExone Biologic's overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current Payments of Debt is €-0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NurExone Biologic Business Description

Other Exchanges NRXBF:USANRX:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
40GF Score

Get the complete analysis for FRA:J90

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.29
Price